论文部分内容阅读
目的探讨艾塞那肽治疗肥胖2型糖尿病的临床效果。方法选取2012年6月—2015年6月肥胖2型糖尿病患者120例,随机分为A组与B组各60例。A组患者以预混胰岛素(诺和锐30)作为治疗药物;B组患者以艾塞那肽作为治疗药物,比较两组干预前后BMI、FBG、2 h PBG、Hb A1c、空腹C肽、餐后2 h C肽、TG及TC。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果两组患者干预前BMI、FBG、2 h PBG、Hb A1c、餐后2 h C肽、空腹C肽、TG及TC比较,差异均无统计学意义(均P>0.05),干预后两组的血糖指标、血脂指标、C肽水平均有所改善,但B组改善幅度优于A组,差异均有统计学意义(均P<0.05)。结论艾塞那肽治疗肥胖2型糖尿病的临床效果确切,可有效降低血糖水平和血脂水平,改善β细胞功能,有效降低体重。
Objective To investigate the clinical efficacy of exenatide in the treatment of obese type 2 diabetes mellitus. Methods From June 2012 to June 2015, 120 patients with obese type 2 diabetes mellitus were randomly divided into group A and group B, 60 cases each. Group A patients with premixed insulin (Novo Rui 30) as a therapeutic drug; Group B patients with exenatide as a treatment drug, compared before and after intervention BMI, FBG, 2 h PBG, Hb A1c, fasting C-peptide, meal After 2 h C peptide, TG and TC. Measurement data were compared using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results There was no significant difference in BMI, FBG, 2 h PBG, Hb A1c, 2 h postprandial C peptide, fasting C-peptide, TG and TC between the two groups (all P> 0.05) (P <0.05). However, the improvement of B group was better than that of A group (all P <0.05). Conclusion Exenatide treatment of obese type 2 diabetes clinical effect is exact, can effectively reduce blood glucose levels and blood lipid levels, improve β-cell function, reduce weight.